Immunotherapy improves survival, quality of life in rapidly progressing head and neck cancer

Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment-resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial co-led by investigators. The new trial was considered so successful that it was stopped early to allow patients in the chemotherapy group to receive the new drug.